Novo Nordisk A/S vs Invesco Solar ETF — how do they compare? Novo Nordisk A/S trades at $46.03 (market cap $207.85B), while Invesco Solar ETF trades at $53.16. The key difference: Novo Nordisk A/S pays a 3.81% dividend while Invesco Solar ETF pays none. Which is the better fit depends on your goals.
| NVO | TAN | |
|---|---|---|
Market Cap | $207.85B | — |
Sector | Health | Sector/Thematic |
52-Week High | $63.98 | $73.95 |
52-Week Low | $35.29 | $36.62 |
Enterprise Value | $222.55B | — |
Dividend Yield | 3.81% | — |
Signals from Pluang's Aura AI — not financial advice
NVO trades at $47.73, up 0.99% today, with a neutral technical signal and strong fundamentals, including a P/E of 11.62 and net income margin of 35.35%. Recent Q2 2026 earnings beat expectations, but the stock faces mixed sentiment due to competitive pressures and pricing headwinds in its GLP-1 portfolio.
The outlook is cautiously optimistic, supported by robust profitability and analyst buy ratings (57.9%), but risks include intense competition from Eli Lilly and margin compression. Upside potential hinges on execution against guidance, while downside risks stem from market share erosion.
No Aura AI signal available yet.
Trailing returns across standard periods
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →TAN is a thematic ETF that tracks the MAC Global Solar Energy Index. It provides targeted exposure to the global solar industry, including manufacturers of solar panels, installers, and component suppliers like Enphase and First Solar.
Read more on TAN →